MHRA has decentralised slots available
This article was originally published in Scrip
Executive Summary
Cancellations and delays have left the UK's Medicines and Healthcare products Regulatory Agency with spare capacity to evaluate product filings under the EU's decentralised procedure in all therapy areas.